The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan
Jichi Medical University and CureApp, Inc. The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan Verifying the standalone therapeutic efficacy of the app in patients untreated with anti hypertensive drugs A new treatment for hypertension, the disease with the highest number of patients in Japan, incurring medical costs in the order of $17 billion USD CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device “Digital Therapeutics” mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics“ for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine. This study will evaluate the efficacy and safety of "Digital Therapeutics" in p